RHY
Rhythm Biosciences Limited
🇦🇺 ASX
🩺 HEALTH CARE
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-13.39%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
12
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Rhythm Biosciences Ltd. engages in the research, development, and commercialization of medical diagnostics technologies. The firm is engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. The company is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives. The firm has developed ColoSTAT, a blood test for the detection of Colorectal Cancer (CRC). If diagnosed early, colorectal cancer is curable. The ColoSTAT Test-Kit measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. The company is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards. The company is focused on working with likeminded global partners to achieve commercialization and distribution of these simple solutions.
📈 Performance
Price History
-69.42%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.06
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in RHY
12
📊 Total Capital Earnings
$19K
🔃 Average investment frequency
27 weeks
💵 Average investment amount
$1,615
⏰ Last time a customer invested in RHY
115 days
RHY investor breakdown
💵 Income of investors
More than 200k
7%
150k - 200k
27%
100k - 150k
27%
50k - 100k
27%
Less than 50k
13%
👶 Age of investors
18 - 25
26 - 34
17%
35 - 90
83%
🙋 Legal gender of investors
Female
50%
Male
50%
Pearlers who invest in RHY also invest in...
Rhythm Biosciences Ltd. engages in the research, development, and commercialization of medical diagnostics technologies. The firm is engaged in the development and commercialization of Australian medical diagnostics technology for sale in domestic and international markets. The Company’s ColoSTAT a blood-base cancer test, designed for the early detection of colorectal cancer, has been developed initially as an alternative screening test for individuals unable to or unwilling to use available screening modalities. ColoSTAT is indicated to screen adults, aged 40 to 85, at average risk for developing Colorectal Cancer (CRC). The test-kit measures five specific biomarkers in the blood that either increase or decrease in quantity when CRC tumors are present.
🩺 HEALTH CARE
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.79%
📊 Share price
$102.61 AUD
🇦🇺 AUSTRALIA
💸 FINANCIALS
🧱 MATERIALS
⛳️ DIVERSIFIED
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
12.27%
📊 Share price
$126.64 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
🙌 Performance (5Yr p.a)
23.83%
📊 Share price
$43.22 AUD
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
🇺🇸 UNITED STATES
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.57%
📊 Share price
$66.42 AUD
⛳️ DIVERSIFIED
🕊️ SOCIALLY AWARE
🌏 GLOBAL
Want more shares? Try these...
Ridley Corp. Ltd. engages in the production and market of stock feed and animal feed supplements. The company is headquartered in Melbourne, Victoria and currently employs 660 full-time employees. The firm operates through two segments: Packaged Feeds and Ingredients and Bulk Stockfeeds. The Packaged Feeds and Ingredients segment comprises animal nutrition feed and ingredient solutions delivered in packaged form, ranging from one ton down to three kilogram bags. The company also includes the Aquafeed Business Unit. The Bulk Stockfeeds segment includes animal nutrition stockfeed solutions delivered in bulk. Its specialist areas include Aqua Feeds, Bulk Ruminant Stockfeeds, Bulk Monogastric Stockfeeds, Animal Proteins & Oils, Commodities, NovaqPro, and Primo Aquaculture. The company manufactures and supplies a complete range of prawn/shrimp feeds and fish feeds for species, including Monodon, Vannamei, Banana, and Stylirostris prawns. The company is also a provider of dairy feed, cattle feed, and sheep feed. The company provides bulk stockfeed for monogastric animals, including layers, broilers, pigs, and ducks.
🙌 Performance (5Yr p.a)
31.17%
📊 Share price
$2.52 AUD
📈 HIGH PRICE GROWTH
🍔 FOOD PRODUCTS
Red Hawk Mining Ltd. engages in the development of mineral deposits. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-02-20. The firm is focused on developing its 100%-owned Blacksmith Iron Ore Project in the Pilbara region of Western Australia. The Blacksmith Project is located approximately 70km north-west of Tom Price and consists of mining lease M47/1451, which covers approximately 112 square kilometers (km2). The Blacksmith Project comprises seven shallow deposits: Ajax, Badger, Blackjack, Champion, Delta, Eagle and Paragon. In addition to the Blacksmith Project, the Company holds retention license R47/21 for the Anvil Project. Its Canegrass Project is located approximately 60 km south-east of Mt Magnet in the Murchison region of Western Australia. The tenement package comprises six granted exploration licenses, which are being explored for battery minerals, particularly vanadium and titanium.
🙌 Performance (5Yr p.a)
318.78%
📊 Share price
$0.83 AUD
⛏️ MINING
Resonance Health Ltd. operates as a healthcare company, which involves in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. The company is headquartered in Perth, Western Australia. The firm specializes in the development and delivery of non-invasive medical imaging software and services. The firm is engaged in the development and commercialization of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its portfolio includes Core Lab and artificial intelligence (AI) powered products to partner with clinicians and radiologists for diagnosis, and management of patients in a variety of clinical settings. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The firm's other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The firm also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart.
🙌 Performance (5Yr p.a)
-10.31%
📊 Share price
$0.06 AUD
🩺 HEALTH CARE